0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover215.53%IV-113.68%PremiumOct 18, 2024Expiry Date10.64Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8963Delta0.0401Gamma0.87Leverage Ratio-0.0192Theta-0.0069Rho-0.78Eff Leverage0.0039Vega
Arcutis Biotherapeutics Stock Discussion
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
Arcutis Biotherapeutics reported strong Q2 2024 financial results, with net product revenues of $30.9M for the ZORYVE franchise, representing a 547% increase year-over-year and 43% growth quarter-over-quarter. The company saw improved gross-to-net (GTN) margins, now in the high 50% range. Arcutis entered a co-promotion agreement with Kowa Pharmaceuticals to expand ZORYVE's reach in primary care and pediatric offices. They also submitted an sNDA for ZORYV...
No comment yet